Here is an interesting e-mail I received the other day:
Hello Ted,
As someone who blogs about MS, I thought you may be interested in sharing the following information with your audience.
Health Canada has approved a change to the TYSABRI
Product Monograph to assist physicians and patients with multiple
sclerosis (MS) make better-informed decisions about treatment with
TYSABRI - for patients with relapsing-remitting form
of MS.
The new label identifies anti-JC virus (JCV)
antibody status as a risk for developing an uncommon, but serious, brain
infection known as progressive multifocal leukoencephalopathy (PML).
The new label states that:
·
Anti-JCV antibody negative status indicates that exposure to the JC virus has not been detected;
·
Patients who are anti-JCV antibody positive have a higher risk of developing PML;
·
Patients who are anti-JCV antibody positive,
have received prior immunosuppressant (IS) therapy and have received
treatment with TYSABRI for more than two years have the highest risk of
developing PML.
GCI GROUP :
changeRULES
Do any of my readers have experience with Tysabri that they can share?
Posts
No comments:
Post a Comment